Selection of Abstracts & Publications by Cytopeutics

In collaboration with local and international medical institutions, academia and research organizations, Cytopeutics® has published many findings in international peer-reviewed journals as well as international conferences.
Heart Attack and Heart Failure

Synergistic effects of intracoronary infusion of autologous bone marrow-derived mesenchymal stem cells and revascularization procedure on improvement of cardiac function in patients with sever ischemic cardiomyopathy

Autologous MSC infusion improves ejection fraction and wall thickness in severe ischemic cardiomyopathy: Results from a clinical multicenter phase ll/lll randomized controlled trial

Cryopreserved mesenchymal stromal cell treatment is safe and feasible for severe dilated ischemic cardiomyopathy

Improved cells survival and paracrine capacity of human embryonic stem cell-derived mesenchymal stem cells promote therapeutic potential for pulmonary arterial hypertension

Pulmonary arterial hypertension, pulmonary fibrosis and pneumonitis

Mesenchymal stromal cells (Cyto-MSC) are well-tolerated and associated with renal function improvement in patients with chronic kidney disease: An observation retrospective study

Acute stroke and other brain / spinal conditions

BM-MSC accelerates acute stroke recovery in a randomized placebo- controlled clinical phase ll/lll study

Generating neuron-like cells from BM-derived mesenchymal stromal cells in vitro

Allogenic cord-derived MSC infusion is safe and improves metabolic functions of uncontrolled diabetes patients

Allogenic Wharton’s jelly mesenchymal stromal cells intravenous infusion increase serum insulin like growth factor 1 and dehydroepiandrosterone in healthy volunteers

Dose-dependent immunomodulatory effect of intravenous allogenic umbilical cord-derived mesenchymal stromal cells (Cytopeutics CLV-100) infusion in healthy volunteers

Autologous bone marrow mesenchymal stromal cells can treat arthritic joints of rheumatoid arthritis patients: Reports of two patients

Cytopeutics® umbilical cord mesenchymal stromal cells (CYTO-MSC) for patients with grade ll-lv acute graft-versus-host disease: A phase l/ll clinical study-protocol overview

A safe and simple approach to obtaining sufficient cytokine induced killer (CIK) cells from criticallyill cancer patients without the need for apheresis or peripheral mobilization

Arthroscopic evidence of cartilage regeneration in severe knee cartilage defects and osteoarthritis following treatment with allogenic umbilical cord-derived mesenchymal stromal cells (Chondrocell- Ex)

Intra articular injection of autologous bone-marrow-derived mesenchymal stromal cells in patients with moderate to severe osteoarthritis

Critical limb ischemia and poorly-healing wounds
Osteoarthritis (OA) and sports injuries
Autoimmune disease and other inflammatory conditions
Graft versus host disease (GvHD)
Diabetes complication + metabolic dysfunction
Chronic kidney disease, diabetic nephropathy and glomerulonephritis

Combination BM-MSC with BM-MNC is better than BM-MNC alone in resolution of large ischemic ulcers: A phase ll/lll clinical randomized study

Umbilical cord-derived mesenchymal stem cell infusion improved liver function in liver cirrhosis and is associated with viral load reduction

Liver inflammation and hepatitis
Macular degeneration, retinal and others eye disease

Autologous cultivated oral mucosal epithelial cells transplantation (COMET) with amniotic membrane-based sheets for severe ocular chemical injury

Safety and efficacy of human Wharton’s jelly-derived mesenchymal stem cells therapy for retinal degeneration

Adjuvant cancer treatment and serious infection

We welcome you to contact us for other related publications that could well provide you with more great insights.